Resistance to anticancer drugs permanently alters electrophoretic mobility of cancer cell lines

被引:4
|
作者
Kazan, Hasan Hueseyin [1 ]
Urfali-Mamatoglu, Cagri [1 ]
Guenduez, Ufuk [1 ]
机构
[1] Middle East Tech Univ, Dept Biol Sci, Univ Mahallesi,Dumlupinar Blv 1, TR-06800 Ankara, Turkey
关键词
Cellular physicochemistry; Cellular morphology; Drug resistance; Electrophoretic mobility; HUMAN-BLOOD PLATELETS; HUMAN-ERYTHROCYTES; LEUKEMIC-CELLS; SOFT PARTICLES; SURFACE-CHARGE; IN-VITRO; NANOPARTICLES; SUSPENSIONS; SEPARATION; ADHESION;
D O I
10.1002/elps.201600494
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Electrophoretic mobility is a physical phenomenon defining the mobility of charged particles in a solution under applied electric field. As charged biological systems, living cells including both prokaryotes and eukaryotes have been assessed in terms of electrophoretic mobility to decipher their electrochemical structure. Moreover, determination of electrophoretic mobility of living cancer cells have promoted the advance exploration of the nature of the cancer cells and separation of cancer cells from normal ones under applied electric field. However, electrophoretic mobility of drug-resistant cells has not yet been examined. In the present study, we determined the electrophoretic mobility of drug-resistant cancer cell lines for both suspension and adherent cells and compared with those of drug-sensitive counterparts. We showed that resistance to anticancer drugs alters the electrophoretic mobility in a permanent manner, even lasting without any exposure to anticancer agents for a long time period. We also studied the cellular morphologies of adherent cells where the cellular invaginations and protrusions were increased in drug-resistant adherent cells, which could be direct cause of altered surface charge and electrophoretic mobility as a result. These findings could be helpful in terms of understanding the electrophysiological and physicochemical background of drug resistance in cancer cells and developing systems to separate drug-sensitive cells from drug-resistant ones.
引用
收藏
页码:1201 / 1205
页数:5
相关论文
共 50 条
  • [41] Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy
    Damaraju, VL
    Damaraju, S
    Young, JD
    Baldwin, SA
    Mackey, J
    Sawyer, MB
    Cass, CE
    ONCOGENE, 2003, 22 (47) : 7524 - 7536
  • [42] Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer
    Yuan, Yueling
    Cai, Tiange
    Xia, Xi
    Zhang, Ronghua
    Chiba, Peter
    Cai, Yu
    DRUG DELIVERY, 2016, 23 (09) : 3350 - 3357
  • [43] Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs
    Mizutani, Satoshi
    Miyato, Yasuyuki
    Shidara, Yujiro
    Asoh, Sadamitsu
    Tokunaga, Akira
    Tajiri, Takashi
    Ohta, Shigeo
    CANCER SCIENCE, 2009, 100 (09) : 1680 - 1687
  • [44] Examination of anticancer drug screening by human cancer cell lines
    Matsui, Megumi
    Kakita, Misato
    Ijiri, Sumiko
    Moriyasu, Matsuko
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 245P - 245P
  • [45] Anticancer Activity of Pterostilbene in Human Ovarian Cancer Cell Lines
    Pei, Hui-lin
    Mu, Dan-mei
    Zhang, Bin
    MEDICAL SCIENCE MONITOR, 2017, 23 : 3192 - 3199
  • [46] CROSS-RESISTANCE TO DIVERSE DRUGS IS ASSOCIATED WITH PRIMARY CISPLATIN RESISTANCE IN OVARIAN-CANCER CELL-LINES
    HAMAGUCHI, K
    GODWIN, AK
    YAKUSHIJI, M
    ODWYER, PJ
    OZOLS, RF
    HAMILTON, TC
    CANCER RESEARCH, 1993, 53 (21) : 5225 - 5232
  • [47] JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs
    Kong, Dexin
    Yamori, Takao
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (06) : 1947 - 1951
  • [48] Irvalec, a novel marine cyclic peptide, enhances the antiproliferative effects of other anticancer drugs in human cancer cell lines
    Serova, Maria
    Astorgues-Xerri, Lucile
    Koumaravel, Jacquelin
    Aracil, Miguel
    Faivre, Sandrine
    Raymond, Eric
    CANCER RESEARCH, 2009, 69
  • [49] Combination of cisplatin-procaine complex DPR with anticancer drugs increases cytotoxicity against ovarian cancer cell lines
    Viale, M
    Pastrone, I
    Pellecchia, C
    Vannozzi, MO
    Cafaggi, S
    Esposito, M
    ANTI-CANCER DRUGS, 1998, 9 (05) : 457 - 463
  • [50] Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents
    Hamberger, Janina
    Liebeke, Manuel
    Kaiser, Maria
    Bracht, Karin
    Olszewski, Ulrike
    Zeillinger, Robert
    Hamilton, Gerhard
    Braun, Dagmar
    Bednarski, Patrick J.
    ANTI-CANCER DRUGS, 2009, 20 (07) : 559 - 572